Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in […]
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $54.00 to $59.00 in a note issued to investors on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a […]
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price objective lifted by Royal Bank of Canada from $51.00 to $56.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about the stock. StockNews.com […]
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target raised by Royal Bank of Canada from $51.00 to $56.00 in a research report report published on Tuesday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock. XENE has been the subject of several other research reports. Cantor […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $30.91 and last traded at $31.13, with a volume of 353275 shares. The stock had previously closed at $32.95. Analyst Ratings Changes A number of equities analysts have recently weighed in on XENE […]